Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target

Table 4

Correlation between UBE2C expression and clinical parameters in OSCC patients ().

Parameters	n	UBE2C (%)		value
		High	Low
		Expression	Expression
Age (years)				0.4882
≥60	29	14	15
<60	11	7	4
Gender				0.7471
Male	23	13	10
Female	17	11	6
Stage				0.4844
	28	17	11
	12	9	3
T classification				0.7471
	24	13	11
	16	10	6
N classification				0.7053
N0	22	18	4
	18	13	5